One-carbon Therapeutics Announces Strategic Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619
Solna, Sweden, March 17h, 2026. One-carbon Therapeutics, a clinical-stage oncology company pioneering first-in-class targeted therapies based on deep understanding into cancer biology, today announced a strategic collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine. The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and […]